

State of Oklahoma SoonerCare

Columvi[™] (glofitamab-gxbm) Prior Authorization Form

Member Name:	Date of Birth:	
	Drug Information	
Physician billing (HCPCS code:) Start Date (or date of next dose):		date of next dose):
Dose:Regimen:		; -
Billing Provider Information		
Provider NPI:Provider Name:		
Provider Phone:	hone: Provider Fax:	
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
including large B-cell lyr i. Has the member B. Is diagnosis diffuse larg i. Used as second oxaliplatin)? Ye- ii. Is member a car iii. Does member in	refractory diffuse large B-cell lyrmphoma (LBCL) arising from folling received 2 or more lines of system B-cell lymphoma (DLBCL)? Ye line and subsequent therapy in some Nombound and the composition of the composition of the proceed to transplant? Albove, please indicate diagnose	es No No Combination with GemOx (gemcitabine and Yes No
4. Has member experienced any a lifyes, please specify adverse reac	ice of progressive disease while adverse drug reactions related to	on glofitamab-gxbm therapy? Yes No Doglofitamab-gxbm therapy? Yes No Doglofitamab-gxbm therapy?
		d all information is true and correct to the

best of my knowledge. Failure to complete this form in full will result in processing delays.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 250 5/6/2025